Therapy Areas: Oncology
Ascelia Pharma and Taiho Oncology partner for gastric cancer study
21 September 2021 -

Swedish biotech company Ascelia Pharma AB (STO:ACE) announced on Tuesday a collaboration agreement with Taiho Oncology Inc, a subsidiary of Taiho Pharmaceutical Co Ltd, for a new global Phase 2 clinical study in gastric cancer.

In the all-oral combination study, Ascelia Pharma's irinotecan chemotherapy tablet Oncoral (ASC-201) will be evaluated in combination with Taiho Oncology's LONSURF (trifluridine and tipiracil) film-coated tablets for oral use.

Following an initial dose-escalation the Phase 2 study will be a randomised, controlled multi-centre study of Oncoral added to LONSURF compared to LONSURF alone.

The primary endpoint will be progression-free survival, with secondary endpoints including response rate, overall survival, pharmacokinetics, safety and tolerability.

Planned to start in the second half of 2021, the study will include approximately 100 patients with metastatic gastric cancer.



Related Headlines